Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: J Neurosci Res. 2010 Oct;88(13):2940–2951. doi: 10.1002/jnr.22438

Figure 3. Inhibition of nSMase2 modifies serum levels of ceramide and sphingomyelin.

Figure 3

Long-term inhibition of nSMase2 decreased ceramide and increased sphingomylein in serum. Figure shows the effects of inhibiting nSMase2 on serum (A) ceramides and (B) sphingomyelins. (n = 12 treated with GW4869, 13 treated with vehicle)* = p < 0.05; *** = p < 0.001 greater than vehicle, ## = p < 0.01; ### = p < 0.001 less than vehicle. Two-way ANOVA with Tukey post hoc comparisons.